France Becomes First Nation to Approve IV Ketamine for Acute Suicidal Crisis

France's Agence nationale de sécurité du médicament et des produits de santé (ANSM) issued the world's first national authorization for intravenous racemic ketamine specifically indicated for the treatment of adult severe suicidal crisis in March 2026. The approval, reported in a correspondence published in The Lancet, represents a full national authorization rather than a pilot program or compassionate use arrangement.

The French authorization addresses what regulators explicitly acknowledge as a global treatment gap: there is currently no officially approved, evidence-based, rapid-acting pharmacological treatment for imminent suicide risk anywhere in the world, including the European Union, United Kingdom, and United States.

Distinguishing IV Ketamine from Existing Treatments

The approval fills a clinical void that Johnson & Johnson's esketamine nasal spray (Spravato查看药品详情) does not address, despite its FDA approval in 2020 for treatment-resistant depression and major depressive disorder with acute suicidal ideation or behavior. Spravato's acute suicidal ideation indication requires two doses over 24 hours in a certified healthcare setting under the existing REMS program, with evidence built around patients who were already somewhat stabilized.

The French authorization specifically targets emergency departments and inpatient units at the moment before stabilization is possible. Racemic ketamine—the 50/50 mixture of R- and S-ketamine used off-label in IV form for years—acts within hours rather than days. According to clinical experience with over 30,000 patients treated through guided ketamine therapy, the IV racemic formulation often produces a perceptible shift within the first session that no oral antidepressant replicates in under six weeks.

Scientific Foundation and Mechanistic Insights

The neuropharmacology underlying this approval has implications for trial designers. Racemic ketamine's R-enantiomer contributes NMDA antagonism with a different receptor binding profile than the S-enantiomer alone, with emerging evidence suggesting the R-ketamine component may drive sustained antidepressant effects with a lower dissociative burden. A 2023 paper in the Journal of Psychopharmacology examining enantiomer-specific signaling suggested the full racemic mixture may produce synergistic AMPA receptor potentiation that neither enantiomer achieves independently.

The evidence base supporting France's decision draws on controlled trial data accumulated over more than a decade. The KETACRISIS trial—a randomized controlled study conducted in France examining IV racemic ketamine against midazolam in adults presenting with acute suicidal crisis—demonstrated significant anti-suicidal effects at 24 hours post-infusion. The trial enrolled patients in genuine psychiatric emergency, used a clinically validated active comparator, and measured outcomes at the moment of highest risk.

Regulatory Implications for the United States

The FDA has historically been uncomfortable with racemic ketamine as a psychiatric product due to scheduling history, abuse liability profile, and the absence of a proprietary sponsor willing to fund a full NDA package. The French approval creates a regulatory precedent that FDA divisions can be asked about directly at Type B meetings, with a specific comparator country and indication on the table.

For sponsors designing acute suicidal crisis trials, the French authorization should be read as a signal rather than a blueprint. The U.S. pathway will require its own endpoint architecture. The Columbia Suicide Severity Rating Scale remains the FDA's preferred primary endpoint in this space, but the agency's 2023 guidance on suicidality assessment in clinical trials emphasizes that change from baseline scores in acutely suicidal inpatient populations must be paired with meaningful time-to-event data—specifically, time to resolution of active suicidal crisis.

Operational Challenges in Trial Design

Enrolling acutely suicidal patients represents one of the hardest recruitment problems in psychiatry. IRBs are cautious, hospital systems are slow to contract, and the consent process for someone in active crisis requires bilingual staff, flexible timing, and site teams that understand the difference between capacity assessment and exclusion. Protocols that fail enrollment fastest are those written by teams who have never observed a consent conversation at 2 a.m. in a busy inpatient unit.

Sites capable of running such trials need existing relationships with inpatient psychiatry units, ED psychiatric liaison programs, and crisis stabilization centers—not just outpatient clinics willing to add visits. The patient population France has now put on the regulatory map is predominantly treatment-refractory, frequently dual-diagnosis, and disproportionately drawn from underserved communities where Spanish-language consent capacity alone eliminates most existing research sites.

Post-Approval Monitoring Considerations

The post-marketing signal detection challenge for a drug used in acute psychiatric emergency differs categorically from standard pharmacovigilance. IV racemic ketamine carries known dissociative and hemodynamic risk profiles. In emergency psychiatric settings where patients may be agitated, medically comorbid, or co-intoxicated, the margin for administration error is narrow. Adverse events in this population are difficult to attribute causally, underreporting in emergency settings is endemic, and the counterfactual outcome without intervention is unknowable.

The next critical signal to monitor is whether any U.S. sponsor files an IND for IV racemic ketamine with an acute suicidal ideation primary indication within the next 18 months. If the French authorization generates that conversation at FDA, the endpoint negotiation that follows will define the entire rapid-acting antidepressant trial landscape for the decade ahead.